Rebecca Chambers - 19 Feb 2025 Form 4 Insider Report for Inari Medical, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 19 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 19:56:37 UTC
Prior SEC filing: 05 Feb 2025
Next SEC filing: 03 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Shannon Trevino, attorney-in-fact for Rebecca Chambers

Key filing fact

Rebecca Chambers filed Form 4 for Inari Medical, Inc. on 19 Feb 2025.

Key facts

This page summarizes Rebecca Chambers's Form 4 filing for Inari Medical, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Feb 2025, 19:56.

Change

Previous filing in this sequence was filed on 05 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NARI transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -9,684
Change %: -100%
Price
Shares after: 0
Date: 19 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Rebecca Chambers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.